ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Disruptive Mood Dysregulation Disorder in a Community Mental Health Clinic: Prevalence, Comorbidity and Correlates

Freeman Andrew J*; Youngstrom Eric A; Youngstrom Jennifer K; Findling Robert L
Journal of Child and Adolescent Psychopharmacology2016-3-1DOI: 10.1089/cap.2015.0061
3被引2阅读
引用收藏
分享

摘要

Objective: The revision of the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5) added a new diagnosis of disruptive mood dysregulation disorder (DMDD) to depressive disorders. This study examines the prevalence, comorbidity, and correlates of the new disorder, with a particular focus on its overlap with oppositional defiant disorder (ODD), with which DMDD shares core symptoms. Methods: Data were obtained from 597 youth 6-18 years of age who participated in a systematic assessment of symptoms offered to all intakes at a community mental health center (sample accrued from July 2003 to March 2008). Assessment included diagnostic, symptomatic, and functional measures. DMDD was diagnosed using a post-hoc definition from item-level ratings on the Schedule for Affective Disorders and Schizophrenia for School-Age Children that closely matches the DSM-5 definition. Caregivers rated youth on the Child Behavior Checklist. Results: Approximately 31% of youth met the operational definition of DMDD, and 40% had Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) diagnoses of ODD. Youth with DMDD almost always had ODD (odds ratio [OR]=53.84) and displayed higher rates of comorbidity with attention-deficit/hyperactivity disorder (ADHD) and conduct disorder than youth without DMDD. Caregivers of youth with DMDD reported more symptoms of aggressive behavior, rule-breaking, social problems, anxiety/depression, attention problems, and thought problems than all other youth without DMDD. Compared with youth with ODD, youth with DMDD were not significantly different in terms of categorical or dimensional approaches to comorbidity and impairment. Conclusions: The new diagnosis of DMDD might be common in community mental health clinics. Youth with DMDD displayed more severe symptoms and poorer functioning than youth without DMDD. However, DMDD almost entirely overlaps with ODD and youth with DMDD were not significantly different than youth with ODD. These findings raise concerns about the potentially confusing effects of using DMDD in clinical settings, particularly given that DSM-5 groups DMDD with depressive disorders, but ODD remains a disruptive behavior disorder, potentially changing the decision-making framework that clinicians use to select treatments.

相关
加载中…
  • Disruptive Mood Dysregulation Disorder and Bipolar Disorder Not Otherwise Specified: Fraternal or Identical Twins?
    Fristad Mary A*; Wolfson Hannah; Algorta Guillermo Perez; Youngstrom Eric A; Arnold L Eugene; Birmaher Boris; Horwitz Sarah; Axelson David; Kowatch Robert A; Findling Robert LJournal of Child and Adolescent Psychopharmacology, 2016, 26(2): 138-146.被引 2
  • Child Maltreatment, other Trauma Exposure, and Posttraumatic Symptomatology among Children with Oppositional Defiant and Attention Deficit Hyperactivity Disorders
    Julian D., Ford; Robert, Racusin; Cynthia G., Ellis; William B., Daviss; Jessica, Reiser; Amy, Fleischer; Julie, ThomasChild Maltreatment, 2000, 5(3): 205-217.被引 187
  • From DSM to DM-ID
    Fletcher Robert J*; Barnhill Jarrett; McCarthy Jane; Strydom AndreJournal of Mental Health Research in Intellectual Disabilities, 2016, 9(3): 189-204.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Child and Adolescent Psychopharmacology
发表日期
2016-03-01
卷期
第 26 卷, 第 2 期
页码
123-130
DOI
10.1089/cap.2015.0061
语言
ENGLISH
成果收录
SSCI
资助标注
National Institute of Mental Health (NIMH); Alcobra; American Academy of Child & Adolescent Psychiatry; American Physician Institute; American Psychiatric Press; AstraZeneca; Bracket; Bristol-Myers Squibb; CogCubed; Cognition Group; Coronado Biosciences; Dana Foundation; Elsevier; Forest; GlaxoSmithKline; Guilford Press; Johns Hopkins University Press; Johnson and Johnson; Jubilant Clinsys; KemPharm, Lilly; Lundbeck; Merck; National Institutes of Health (NIH); Neurim; Novartis; Noven; Otsuka; Oxford University Press; Pfizer; Physicians Postgraduate Press; Purdue; Rhodes Pharmaceuticals; Roche; Sage; Shire; Sunovion; Supernus Pharmaceuticals; Transcept Pharmaceuticals; Validus; WebMD

作者

  • F

    Freeman Andrew J (通讯) (第一作者)

  • Y

    Youngstrom Eric A

查看全部 4 位作者收起作者
  • Y

    Youngstrom Jennifer K

  • F

    Findling Robert L

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417